DLA Piper, one of the largest law firms in the world, has gone from publicly denouncing Donald Trump to actively representing him in multiple legal matters. In January 2021, the firm was
Power Probe chief executive Chema Garcia says he remains committed to the company’s London listing despite a sharp fall in its share price since debuting on the Aim market. The North Carolina-based
More
New York State has enacted a landmark law giving employees the right to inspect their personnel records, effective November 8, 2026. Governor Kathy Hochul signed Senate Bill S3460 on September 9, 2026,
More
Weil insiders have made little effort to conceal their indifference toward the departure of Mike Aiello, one of the firm’s most prominent partners. The reaction from within the firm has been notable
More
The FTSE 100 rose at the start of a pivotal week for global monetary policy, with defensive stocks leading gains across the index. Investors rotated into traditionally safer sectors as markets braced
More
Novo Nordisk is streamlining its public identity, adopting “Novo” as its everyday brand name while retaining Novo Nordisk A/S as its legal global company name. The move places the Danish pharmaceutical giant
More
A significant challenge to federal patent policy has failed without a court ever ruling on whether the disputed practice was actually lawful. The Federal Circuit’s decision in US Inventor, Inc. v. Squires,
More
The Department of Justice has entered a Florida courtroom to defend both government lawyers and Donald Trump’s personal attorneys against potential sanctions. The intervention comes eight months after Trump filed a lawsuit
More
SFL Corporation (SFL) has secured a seven-year charter extension, a move that analysts suggest keeps the company’s valuation broadly in line with its intrinsic worth. Charter extensions of this length are considered
More
Cautious sentiment is building around one particular FTSE 250 stock, with analysts and private investors urging patience before taking any position. The FTSE 250 index is home to a broad range of
More
The U.S. biopharmaceutical market is no longer operating under a single dominant economic model, according to industry analyst Bill Roth. Writing in the final instalment of his Great Repricing series, Roth argues
More